Patent intelligence · US
US 9757514
Device, system and methods for the oral delivery of therapeutic compounds
Device, system and methods for the oral delivery of therapeutic compounds
Patent details — US 9757514
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 12, 2017
- Expiration
- Sep 7, 2037
- Applicant
- Rani Therapeutics, LLC
- Claims
- 6
- CPC classes
- A61K, A61K38/13, A61K38/21, A61K38/26
Quick answer
US 9757514 (Device, system and methods for the oral delivery of therapeutic compounds) is held by Rani Therapeutics, LLC. Status: granted. Granted Sep 12, 2017. Expires Sep 7, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Rani Therapeutics, LLC
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K38/13, A61K38/21, A61K38/26, A61K38/27, A61K38/28
More from Rani Therapeutics, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12357555
Self-emulsifying composition, intended for administration onto the skin, containing biosurfactant, cosurfactant and oil phase
granted -
US 12268831
Swallowable drug delivery device and methods of drug delivery
granted -
US 12263325
Device, system and methods for the oral delivery of therapeutic compounds
granted -
US 12214019
Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
granted -
US 12201721
Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
granted -
US 12168692
Antibodies targeting CCR2
granted -
US 12128133
Ingestible device with expandable enclosure
granted -
US 12077551
Zinc complex, preparation thereof and use thereof for trerapy of human and animal diseases
granted
Related coverage
Rise of Biosimilars in US: FDA Approval Trends & Market Impact
The article delves into the growing presence of biosimilars in the US market, focusing on FDA approval trends and their implications for drug pricing and patient access.
FDA Approves Stelara: New Ulcerative Colitis Treatment from J&J
Stelara, recently approved by the FDA, provides a new treatment option for ulcerative colitis, promising improved outcomes for patients.
FDA Approves First Interchangeable Biosimilar for Stelara (Ustekinumab)
The FDA has approved the first interchangeable biosimilar for Stelara (Ustekinumab), expanding treatment options for patients with psoriasis and Crohn's disease.
Frequently asked questions
What is US patent 9757514?
US 9757514 (Device, system and methods for the oral delivery of therapeutic compounds) is held by Rani Therapeutics, LLC. Status: granted. Granted Sep 12, 2017. Expires Sep 7, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9757514?
Rani Therapeutics, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 148 pharmaceutical patents for this assignee.
When does US 9757514 expire?
Our index shows an expiration date of Sep 7, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.